Characteristics of patients with systemic sclerosis living in Qatar

Objective: The aim of this study was to determine the demographic, clinical, and immunological characteristics of patients with systemic sclerosis living in Qatar. Method: This retrospective study included 42 patients with systemic sclerosis who attended Rheumatology Clinics at Hamad General Hospital in Doha, Qatar, between January 2000 and December 2014. All patients fulfilled the 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis. Results: The 42 consecutively recruited patients of mixed ethnicities consisted of 37 (88.1%) females and 5 (11.9%) males. Of the total 42 patients, 22 (52.4%) had diffuse cutaneous systemic sclerosis (dcSSc) and 20 (47.6%) had limited cutaneous systemic sclerosis (lcSSc). Mean age at onset of first symptoms was 34.5 ± 12 years, and mean age at diagnosis was 36.1 ± 11.5 years. During follow-up, Raynaud's phenomenon occurred in 36 (85.7%) patients, sclerodactyly in 39 (92.9%) patients, digital ulcers in 16 (38.1%) patients, calcinosis in 6 (14.3%) patients, telangiectasia in 16 (38.1%) patients, and arthritis in 13 (31%) patients. The gastrointestinal and respiratory systems were the most frequently affected internal organs. Gastrointestinal involvement was present in 36 (85.7%) patients, and respiratory involvement was found in 30 (71.4%) patients. The majority of patients had positive antinuclear antibodies (ANA; 97.6%). Anti-Scl-70 antibody was found in 66.7% and anti-centromere antibody (ACA) was detected in 14.3% of the patients. Conclusion: To our knowledge, this is the first study that describes the clinical and immunological profile of patients with systemic sclerosis living in Qatar. This study cohort showed an earlier age of disease onset and diagnosis than that reported in other international studies. Furthermore, in contrast to several other studies, the diffuse type of scleroderma was more commonly observed than the limited type, which resulted in a high frequency of anti-Scl-70 antibody and interstitial lung disease.

[1]  C. Ng,et al.  Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort , 2015, International journal of rheumatic diseases.

[2]  S. Chatterjee,et al.  Evaluation and management of gastrointestinal manifestations in scleroderma , 2014, Current opinion in rheumatology.

[3]  R. Domsic.  Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement , 2014, Current opinion in rheumatology.

[4]  C. Feghali-Bostwick,et al.  Update on scleroderma-associated interstitial lung disease , 2014, Current opinion in rheumatology.

[5]  S. Kaveri,et al.  Clinical and Autoimmune Profile of Scleroderma Patients from Western India , 2014, International journal of rheumatology.

[6]  R. Silver,et al.  Systemic sclerosis and the heart. , 2014, Rheumatic diseases clinics of North America.

[7]  Hanan Darweesh,et al.  Frequency of disease subsets and patterns of organ involvement among Egyptian patients with systemic sclerosis - A retrospective study , 2013 .

[8]  M. Moradi-Lakeh,et al.  Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients , 2013, Rheumatology International.

[9]  V. Steen,et al.  Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management , 2012, Current opinion in rheumatology.

[10]  J. Callejas-Rubio,et al.  Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. , 2012, Seminars in arthritis and rheumatism.

[11]  A. Hashimoto,et al.  Clinical features of 405 Japanese patients with systemic sclerosis , 2012, Modern rheumatology.

[12]  K. Ali,et al.  Prevalence of interstitial lung disease among patients with systemic sclerosis in Iraqi Kurdistan , 2012, Arthritis Research & Therapy.

[13]  Y. Braun-Moscovici,et al.  Scleroderma - new aspects in pathogenesis and treatment. , 2012, Best practice & research. Clinical rheumatology.

[14]  T. Skare,et al.  Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil. , 2011, Anais brasileiros de dermatologia.

[15]  C. Denton,et al.  Clinical and Serological Hallmarks of Systemic Sclerosis Overlap Syndromes , 2009, The Journal of Rheumatology.

[16]  C. Denton,et al.  Evidence-based management of rapidly progressing systemic sclerosis. , 2010, Best practice & research. Clinical rheumatology.

[17]  A. Wells,et al.  Scleroderma lung disease: evolving understanding in light of newer studies , 2008, Current opinion in rheumatology.

[18]  M. Kahaleh,et al.  Raynaud phenomenon and the vascular disease in scleroderma , 1994, Current opinion in rheumatology.

[19]  A. Silman,et al.  Epidemiology of systemic sclerosis. , 1996, Current opinion in rheumatology.

[20]  V. Steen,et al.  Autoantibodies in systemic sclerosis. , 1996, Bulletin on the rheumatic diseases.